o MEN2A with cutaneous lichen amyloidosis (CLA) o MEN2A with Hirschsprung's disease (HD) o Familial medullary thyroid cancer (FMTC) was once considered to be a separate subtype from MEN2A, and is now widely considered to be a variant of MEN2A with decreased penetrance of pheochromocytoma and primary hyperparathyroidism (PHPT). 1 MEN 2A should be suspected in individuals with one or more specific endocrine tumors-medullary thyroid cancer (and/or its precursor, C-cell hyperplasia), pheochromocytoma, or parathyroid adenoma/hyperplasia.
o Approximately 95% of individuals will have medullary thyroid cancer (MTC), typically at a younger age of onset than sporadic MTC, as a presenting symptom. The MTC is more often associated with C-cell hyperplasia and tends to be multifocal or bilateral.
o Approximately 50% of individuals with MEN2A will develop pheochromocytoma (PCC). PCC has the tendency to be adrenal and bilateral. [3] [4] [5] PCC is the first sign in approximately 13-27% of individuals with MEN2A. 6, 7 o Approximately 20-30% of individuals with MEN2A will develop primary hyperparathyroidism. 1
MEN2B
MEN2B should be suspected in individuals with distinctive facies (including lip mucosal neuromas resulting in thick vermilion of the upper and lower lip), mucosal neuromas of the lips and tongue, medullated corneal nerve fibers, marfanoid habitus, and MTC. 
Cause
Over 95% cases of MEN 2 are due to mutations in RET, a proto-oncogene and tyrosine kinase. Gain of function mutations allow activation without dimerization of the protein or dimerization of the protein in the absence of ligand (constitutive activation). 2 Pathogenic variants have been reported in exons 5, 8, 10, 11, 13, 14, 15, and 16 (with mutations in exons 10 and 11 comprising 95% of individuals with MEN2A). Genotypephenotype correlations are known for RET mutations. 1
Inheritance
MEN2 is inherited in an autosomal dominant pattern, meaning that an affected individual has inherited one RET mutation from an affected parent. MEN2 can also result from a new (de novo) RET mutation in the affected individual.
Individuals with MEN2 have a 50% chance of passing the mutation to their children.
Additionally, parents and siblings of known carriers have a 50% chance of being carriers of the same mutation.
Approximately 5-9% of MEN2A and 50% of MEN2B are caused by de novo RET mutations not inherited from an affected parent. 1, 2 Siblings would still need to be tested to rule out germline mutations.
MEN2 is associated with high penetrance and variable expressivity.
Diagnosis
The diagnosis of MEN2 is established based on clinical presentation, family history, and genetic testing. Identification of a pathogenic RET variant establishes the diagnosis if clinical features are inconclusive. 2 Genetic testing to identify germline RET mutations is indicated in all individuals with primary C-cell hyperplasia or medullary thyroid cancer or a clinical diagnosis of MEN2, regardless of whether there is a family history.
MEN2A
o The occurrence of two or more specific endocrine tumors (medullary thyroid cancer, pheochromocytoma, and/or parathyroid adenoma/hyperplasia) in the patient or in close relatives o Familial medullary thyroid carcinoma (FMTC) is suspected in families with four or more cases of MTC in the absence of pheochromocytoma or parathyroid adenoma/hyperplasia. 2 However, distinguishing this subtype from classical MEN2A can be challenging for some small families.
MEN2B
o The presence of early-onset medullary thyroid cancer, mucosal neuromas of the lips and tongue, medullated corneal nerve fibers, distinctive facies with enlarged lips, and a marfanoid body habitus. 2
Test information Introduction
Testing for MEN2 may include targeted mutation analysis, sequence analysis, or known familial mutation testing.
Targeted mutation analysis
Targeted mutation analysis use hybridization, single nucleotide extension, select exon sequencing, or similar methodologies to assess a set of disease-causing mutations.
This analysis identifies common and/or recurring mutations.
Targeted mutation panels or select exon sequencing may have differing clinical sensitivities dependent upon patient ethnicity, phenotypic presentation, or other casespecific characteristics.
RET targeted sequencing may evaluate exons 5, 8, 10, 11, and 13-16, where most disease-causing mutations have been reported. Such testing will detect 98% of mutations associated with MEN2A and 95% of mutations associated with FMTC. [8] [9] [10] [11] Targeting 2 RET mutations (p.Met918Thr and p.Ala883Phe) will detect 98% of RET mutations associated with MEN2B. 12, 13 As the phenotype is distinct from MEN2A, targeting these two mutations may be more efficient than select exon sequencing for MEN2B.
Full Gene Sequence analysis
Sequence analysis detects single nucleotide substitutions and small (several nucleotide) deletions and insertions. Regions analyzed typically include the coding sequence and intron/exon boundaries. Promoter regions and intronic sequences may also be sequenced if disease-causing mutations are known to occur in these regions of a gene.
Results may be obtained that cannot be adequately interpreted based on the current knowledgebase. When a sequence variation is identified that has not been previously 
RET Full Gene Sequencing
 Genetic Counseling:
o Pre-and post-test genetic counseling by an appropriate provider (as deemed by the Health Plan policy), AND
